Items tagged with Research and development
WGNV newsletter: Latest updates on TB vaccines (post)
The Stop TB Partnership Working Group on New TB Vaccines (WGNV) released a newsletter with the latest updates related to the TB vaccine research and development.
UCT prof calls for increased investment in TB vaccine research (post)
During a panel discussion of the United Nations High-level Meeting on TB held in New York City on 22 September 2023, Professor Mark Hatherill, the director at the South African Tuberculosis Vaccine Initiative (SATVI) based at the University of Cape Town (UCT), called for a quantum jump in TB vaccine research and development (R&D) funding, to deliver the transformative tools needed to end the TB pandemic.
TB Vax ARM: What's next for TB R&D post-HLM? A pre-Union virtual meeting (post)
In preparation for the Union World Conference on Lung Health in Paris, France on 15-18 November 2023, the TB Vaccine Advocacy Roadmap (TB Vax ARM) will host a virtual meeting on 2 November 2023 exploring what’s next for TB research and development (R&D) following the United Nations High-Level Meeting on TB (HLM).
University of Montana leads $12.3M contract to advance TB vaccine (post)
MISSOULA, 23 October 2023 – The National Institutes of Health recently awarded a $12.3 million contract to the University of Montana to develop a novel vaccine adjuvant for use in a tuberculosis vaccine. Adjuvants are substances that boost the effectiveness of vaccines.
Routine vaccines – Tuberculosis (post)
Efforts to fight the world’s biggest infectious killer are about to get a boost, with new vaccines on the horizon.
BRICS TB research summit opens in South Africa (post)
JOHANNESBURG, Dec. 11 (Xinhua) -- The BRICS Tuberculosis Research Network Innovation Summit kicked off on Monday in Durban, South Africa's coastal city, with scientists and senior officials from BRICS countries gathering together to facilitate collaborative research on innovations in tuberculosis diagnostics, vaccines, therapeutics and drugs and health systems strengthening.
WGNV newsletter: Latest updates on TB vaccines (post)
The Stop TB Partnership Working Group on New TB Vaccines (WGNV) released a newsletter with the latest updates related to TB vaccines.
Bill & Melinda Gates Medical Research Institute initiates Phase 3 clinical trial of TB vaccine candidate (post)
-- A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
-- Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries
-- The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective
BioVersys announces expansion of strategic collaboration with GSK (post)
BioVersys AG announced the expansion of its strategic collaboration with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of TB.
Consensus statement: The inclusion of children and adolescents in TB diagnostic development and evaluation (post)
Using an online Delphi process, stakeholders from academia, industry, government, funding agencies, and advocacy achieved consensus on an approach to include children and adolescents in TB diagnostic tool development and evaluation.
Page 17 of 28 · Total posts: 0
←First 16 17 18 Last→